Online inquiry

IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3001MR)

This product GTTS-WQ3001MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3001MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1299MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ2441MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ1206MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ15494MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ7864MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ4381MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ4223MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ9308MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMP-321
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW